ClinicalTrials.Veeva

Menu

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

Hengrui Medicine logo

Hengrui Medicine

Status and phase

Enrolling
Phase 2

Conditions

Type 2 Diabetes

Treatments

Drug: SHR-3167
Drug: Insulin glargine

Study type

Interventional

Funder types

Industry

Identifiers

NCT06688123
SHR-3167-201

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2 subjects.

Enrollment

273 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Able and willing to provide a written informed consent.
  2. Diagnosed with type 2 diabetes mellitus ≥ 6 months prior to the day of screening.
  3. A stable dose of metformin alone or in combination with a stable dose of a SGLT2 inhibitor for 3 months prior to screening.
  4. Body mass index (BMI): 18.5~35.0 kg/m2.
  5. HbA1c of 7.5%~10.0% as assessed by the local laboratory.
  6. Insulin naïve.
  7. Female subjects and partners of male subjects who are of childbearing potential, have no fertility plan and agree to take highly effective contraceptive measures within 6 months after signing the informed consent form to the last dose, and have no plans to donate eggs/sperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.

Exclusion criteria

  1. Electrocardiogram (ECG) results show clinically significant abnormalities that may affect the safety of the subject.
  2. Poor blood pressure control at screening.
  3. Diagnosis or suspicion of type 1 diabetes mellitus, latent autoimmune diabetes mellitus in adult (LADA),other special types of diabetes or secondary diabetes mellitus.
  4. ≥1 episode of severe hypoglycemia or asymptomatic hypoglycemia within 6 months prior to screening, or recurrent hypoglycemic events within 1 month prior to screening.
  5. History of diabetic ketoacidosis or hyperosmolar hyperglycemic state due to hyperglycemia within 6 months prior to screening.
  6. Presence of acute or chronic hepatitis, cirrhosis, or other serious liver disease other than non-alcoholic fatty liver disease.
  7. Those who have a history of severe cardiovascular and cerebrovascular diseases within 6 months before screening.
  8. Malignancy or history of malignancy within 5 years prior to screening.
  9. Received any diabetes mellitus or weight-loss medication outside the inclusion criteria within 3 months prior to screening.
  10. Participation in a clinical trial of any drug or medical device within 3 months prior to screening.
  11. Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

273 participants in 3 patient groups

SHR-3167 group A
Experimental group
Treatment:
Drug: SHR-3167
Drug: SHR-3167
SHR-3167 group B
Experimental group
Treatment:
Drug: SHR-3167
Drug: SHR-3167
Insulin glargine group
Active Comparator group
Treatment:
Drug: Insulin glargine

Trial contacts and locations

2

Loading...

Central trial contact

Jianting Han, B.S

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems